The information you provide to the chat will be recorded to improve your experience and to contact you. Please read our privacy notice to see how we are processing and protecting your data. Click to view our Cookie Notice.
We'd love your feedback—take a quick survey to help us improve.
How can we help you today?
Search Patheon
Recent searches
Clear History
Suggestions
All Results
Thermo Fisher Scientific
Why early matters: Data-driven strategies to de-risk OSD development
How to make informed early decisions to accelerate OSD development and predict problems before they cost you
Late-stage surprises continue to drive cost, delay, and challenges in oral solid dosage (OSD) development—especially for complex, poorly soluble molecules. Too often, formulation and manufacturability risks surface only after significant time and investment.
In a recent panel discussion, GlobalData’s Director of Drugs Intelligence, Quentin Horgan, joins Thermo Fisher Scientific’s Senior Director of Global Technical and Scientific Affairs, Anil Kane, to explore how early insight can change the trajectory of OSD development.
This on-demand webinar focuses on how data-driven characterization, predictive modeling, and Quality by Design (QbD) approaches help teams identify and address risks earlier—when decisions are more flexible and impacts easier to manage, before scale-up begins.
What you’ll learn by watching this webinar:
- Why early development is a critical inflection point
- Shift risk earlier to reduce cost, complexity, and late-stage surprises.
- How data and predictive tools improve decisions
- Reduce trial-and-error and enable smarter formulation and process choices.
- What scalable OSD development looks like
- Achieve smoother scale-up and more efficient paths to commercialization.
- How the OSD market is evolving in 2026
- Understand key trends, players, and growth across therapy areas.
Speaker
Anil Kane
Senior Director, Global Technical & Scientific Affairs
Thermo Fisher Scientific
Anil Kane
Senior Director, Global Technical & Scientific Affairs
Thermo Fisher Scientific